Skip to main content
Quest Diagnostics

The Prevalence and Association of Frailty and Polypharmacy with the Retention of Older Cancer Survivors in the COACH study.

SIOG 2025

International Society of Geriatric Oncology

Ghent, Belgium Nov 20-22, 2025

Poster presentation: The Prevalence and Association of Frailty and Polypharmacy with the Retention of Older Cancer Survivors in the COACH study.

Authors: Krok-Schoen J, Flora L, Armah J, Samami E, Lyon D, Brassil K, Loftis J, Harrison M, Hammer MJ, Halpenny B, Wright A, Lally RM, Jackson M, Schmidt R, Milbury K,  Garay A, Whisenan Mt, Ponce D, Gonzalez A, Thompson M, SaliganL, Arthur EK

Medical Specialty: Oncology

Disclaimer:  One or more of the authors of this publication were employed at the time by Pack Health, a subsidiary of Quest Diagnostics.

Related content

Conference Presentation
Comprehensive Outcomes for After Cancer Health (COACH) Study: 2024 Trial in Progress Updates
Conference Presentation
Comparison of PROMIS Tools and FACT-G in Assessing Cancer Survivors’ Patient-Reported Outcomes during a Randomized Digital Health Coaching Trial.
Audio Podcast
Exploring Digital Pathology and Artificial Intelligence
On-Demand Webinar
Prognostic Melanoma Molecular Testing to Inform Better Patient Care

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.